# Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

> **NCT05546957** · NA · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Aspirin
- **DRUG:** rivaroxaban low dose
- **DRUG:** rivaroxaban high dose

## Key facts

- **NCT ID:** NCT05546957
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-05
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-04-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546957, "Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05546957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*